Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/25/2025

Anemia Management in Children

Diagnosis and Classification

  • Microcytic anemia may be caused by iron deficiency, thalassemia, or sideroblastic anemia, according to the American Academy of Pediatrics 1
  • Normocytic anemia may be caused by acute blood loss, hemolysis, or chronic disease 1
  • Macrocytic anemia may be caused by vitamin B12 or folate deficiency, or bone marrow disorders 1

Treatment

  • Patients with X-linked sideroblastic anemia (XLSA) may be treated with pyridoxine 50-200 mg/day, and maintenance dose of 10-100 mg/day if responsive, as recommended by the American College of Medical Genetics 1
  • Iron chelation therapy may be necessary for patients with XLSA who develop iron overload 1
  • Oral iron supplementation at 3-6 mg/kg/day of elemental iron divided into 1-3 doses may be effective for patients with iron deficiency anemia, according to the Centers for Disease Control and Prevention 1
  • Vitamin B12 deficiency may be treated with intramuscular B12 injections (1000 μg daily for 1 week, then weekly for 4 weeks, then monthly) or oral supplementation (1000-2000 μg daily), with a strength of evidence level of high, according to the National Institutes of Health 2
  • Folate deficiency may be treated with oral folate (1-5 mg daily), with a strength of evidence level of moderate, according to the American College of Medical Genetics 2

Specialized Management

  • Patients with severe anemia may require referral to a pediatric hematologist/oncologist, especially those who require bone marrow aspiration/biopsy or hematopoietic stem cell transplantation, as recommended by the American Society of Hematology 1
  • Hematopoietic stem cell transplantation may be considered for conditions like aplastic anemia, according to the National Marrow Donor Program 1
  • Myelodysplastic syndrome may be treated with supportive therapy, hypomethylating agents (5-azacytidine or decitabine), or allogeneic stem cell transplantation, with strength of evidence levels ranging from moderate to high, according to the European Society for Medical Oncology, American Society of Clinical Oncology, and Center for International Blood and Marrow Transplant Research 3

Follow-up and Prevention

  • Regular follow-up with a pediatric hematologist is essential for patients with severe anemia, according to the American Academy of Pediatrics 1
  • Nutritional counseling for iron-rich foods and iron supplementation for 3-6 months may be necessary to replenish stores in patients with iron deficiency anemia, as recommended by the World Health Organization 1
  • Weekly complete blood counts should be performed until improvement, with a strength of evidence level of moderate, according to the American Society of Clinical Oncology 2
  • Vitamin B12 and folate levels should be monitored if deficiency was identified, with a strength of evidence level of moderate, according to the National Institutes of Health 2

Management of Thrombocytopenia

  • Grade 2 thrombocytopenia (platelets 50-75 × 10^9/L) may be managed with immune checkpoint inhibitors held and prednisone (0.5-1 mg/kg/day), with a strength of evidence level of moderate, according to the Society for Immunotherapy of Cancer 2
  • Grade 3 thrombocytopenia (platelets 25-50 × 10^9/L) may be managed with immune checkpoint inhibitors permanently discontinued, hematology consult, and prednisone (1-2 mg/kg/day), with a strength of evidence level of high, according to the American Society of Clinical Oncology 2
  • Grade 4 thrombocytopenia (platelets <25 × 10^9/L) may be managed with hospitalization, hematology consult, high-dose corticosteroids, and additional immunosuppressive therapy, with a strength of evidence level of high, according to the American College of Emergency Physicians 2
  • Platelet transfusions may be indicated for active bleeding with platelet count <50 × 10^9/L or severe thrombocytopenia (<10-20 × 10^9/L) with high bleeding risk, with a strength of evidence level of moderate, according to the American Association of Blood Banks 2
  • Red blood cell transfusions should be considered for symptomatic anemia or hemoglobin <7-8 g/dL, with a strength of evidence level of high, according to the American Society of Clinical Oncology 2

Management of Thrombotic Thrombocytopenic Purpura

  • Immediate hematology consultation, ADAMTS13 activity level and inhibitor titer, and stabilization of organ dysfunction should be performed if schistocytes are present on peripheral smear with thrombocytopenia and macrocytic anemia, with a strength of evidence level of high, according to the American Society of Hematology 2
  • Plasma exchange therapy should be considered if thrombotic thrombocytopenic purpura is confirmed, with a strength of evidence level of high, according to the National Heart, Lung, and Blood Institute 4